Philip P. Boudreau's Insider Trades & SAST Disclosures
Philip P. Boudreau's most recent trade in Abbott Laboratories was a trade of 4,908 Common shares without par value done at an average price of $135.9 . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Philip P. Boudreau.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | Philip P. Boudreau | EVP AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.87 per share. | 28 Feb 2025 | 4,908 | 56,553 (0%) | 0% | 135.9 | 666,850 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 83,783 | 83,783 | - | - | Option (right to buy) | |
| Abbott Laboratories | Philip P. Boudreau | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 22,495 | 61,461 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Philip P. Boudreau | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.27 per share. | 01 Sep 2024 | 387 | 38,966 (0%) | 0% | 113.3 | 43,835 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | SENIOR VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.05 per share. | 29 Feb 2024 | 1,738 | 39,353 (0%) | 0% | 120.1 | 208,647 | Common shares without par value |
| Abbott Laboratories | Boudreau P. Philip | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 86,519 | 86,519 | - | - | Option (right to buy) | |
| Abbott Laboratories | Philip Boudreau P. | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 23,024 | 41,091 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Philip P. Boudreau | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2023 | 10,223 | 10,223 | - | - | Option (right to buy) | |
| Abbott Laboratories | Philip P. Boudreau | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2023 | 2,620 | 18,067 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 106.00 per share. | 16 Jun 2023 | 8,000 | 15,447 (0%) | 0% | 106 | 848,000 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 1,477 | 23,447 (0%) | 0% | 99.8 | 147,360 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 19,149 | 19,149 | - | - | Option (right to buy) | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 4,855 | 24,924 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 1,192 | 20,069 (0%) | 0% | 122.4 | 145,913 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 24,938 | 24,938 | - | - | Option (right to buy) | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 5,351 | 22,227 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 116.79 per share. | 18 Feb 2022 | 966 | 21,261 (0%) | 0% | 116.8 | 112,819 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 126.49 per share. | 25 Oct 2021 | 8,000 | 16,876 (0%) | 0% | 126.5 | 1,011,920 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 704 | 24,876 (0%) | 0% | 121.6 | 85,592 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 25,613 | 25,613 | - | - | Option (right to buy) | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 4,997 | 26,517 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.04 per share. | 19 Feb 2021 | 937 | 25,580 (0%) | 0% | 123.0 | 115,288 | Common shares without par value |
| Abbott Laboratories | Philip P. Boudreau | VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.23 per share. | 16 Feb 2021 | 943 | 21,520 (0%) | 0% | 128.2 | 120,921 | Common shares without par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges